All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
The Phase 2 trial met its pre-specified efficacy endpoints and showed that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
A key focus of the presentations will be on the development of OCS-01 as a potentially transformative and first topical treatment for Diabetic Macular Edema (DME) and as the first once a day steroid for the treatment of inflammation and pain following ocular surgery.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
Oculis has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for OCS-01 in two indications: for the treatment of inflammation and pain following cataract surgery and for the treatment of diabetic macular edema (DME).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Presentation will highlight results from Oculis's Phase 2 clinical trial, assessing the safety & efficacy of its drug candidate OCS-01 for the treatment of inflammation & pain after cataract surgery.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
Details:
The Phase 2 trial data is the first controlled study of OCS-01 for the treatment of DME.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
